ArticleMolecules (Basel, Switzerland)2021
In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- FAP-Inhibitor Homodimers with Engineered Linker-Spacer Units: Toward Optimized Radiopharmaceuticals.ACS omega · 2026Article
- The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.International journal of molecular sciences · 2026Review
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
- Preclinical evaluation of DOTAGA.Glu.(FAPI)European journal of nuclear medicine and molecular imaging · 2026Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2025Article
- Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.European journal of nuclear medicine and molecular imaging · 2025Article
- Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of theMolecules (Basel, Switzerland) · 2024Article
- Translational assessment of a DATA-functionalized FAP inhibitor with facileEuropean journal of nuclear medicine and molecular imaging · 2023Article
- The effects of novel macrocyclic chelates on the targeting properties of theEJNMMI research · 2023Article
- Head-to-Head Comparison between [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.Cancers · 2023Article
- Tumor microenvironment and fibroblast activation protein inhibitor (FAPI) PET: developments toward brain imaging.Frontiers in nuclear medicine · 2023Review
- AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications.Pharmaceuticals (Basel, Switzerland) · 2022Review
- FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century.Frontiers in oncology · 2022Review
- Dimeric FAPI with potential for tumor theranostics.American journal of nuclear medicine and molecular imaging · 2021Article
- Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.American journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.